Charles River Laboratories International, Inc. (CRL) financial statements and ratios from SEC XBRL: revenue $4.0B (TTM), net margin -3.6%, revenue growth -2.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $4.02B |
| Revenue (TTM) | $4.0B |
| Net Margin | -3.6% |
| Operating Margin (TTM) | 2.3% |
| Net Debt / EBITDA | -0.6 |
| Revenue Growth (YoY) | -2.7% |
| EPS Growth (YoY) | -102.8% |
| FCF Growth (YoY) | -12.2% |
| EV / EBITDA | 36.0 |
| Price / Book | 4.99 |
| Price / Sales | 3.55 |
| FCF Yield | 2.6% |
| Altman Z-Score | 3.12 (safe) |
| Industry P/E (Business Services) | 30.0 |
| Sector P/E (Technology) | 34.1 |
CRL overview · CRL earnings · CRL KPIs · CRL documents · CRL ownership · CRL peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.